After taking into account ENTA’s net cash and its 45.5% ownership of the Mavyret royalty stream, investors are ascribing a negative valuation to ENTA’s pipeline.
I meant to say, “After taking into account ENTA’s net cash and its 45.5% ownership of the Mavyret royalty stream, investors are ascribing a negative valuation to ENTA’s pipeline and potential awards from the Paxlovid patent lawsuit.